Clients CanChew® and AXIM® Biotechnologies were part of a news segment on CBS New York on the company’s ongoing clinical trials for the use of its patented CBD gum for the treatment of irritable bowel syndrome. A legal, non-psychoactive product of the hemp plant, CBD oil shows potential for treating a number of conditions, including IBS. AXIM®’s clinical trial for IBS, which is being completed in the Netherlands, has enrolled 40 IBS patients. If the trials on AXIM®’s Canchew® Plus gum are successful, the company will test it against more severe forms of IBD in the future.

Read the Story HERE or watch below: